Company Overview of MyoKardia, Inc.
MyoKardia, Inc. develops a pipeline of small molecule therapeutics that addresses clinical needs for patients with genetic heart diseases. The company was founded in 2012 and is based in South San Francisco, California.
400 East Jamie Court
South San Francisco, CA 94080
Founded in 2012
Key Executives for MyoKardia, Inc.
Chief Executive Officer and Director
Compensation as of Fiscal Year 2014.
MyoKardia, Inc. Key Developments
Sanofi and MyoKardia, Inc. Announce Collaboration to Develop Targeted Therapies for Patients with Genetic Heart Disease
Sep 17 14
Sanofi and MyoKardia, Inc. announced a worldwide collaboration to discover and develop first-of-its-kind targeted therapeutics for heritable heart diseases known as cardiomyopathies, the most common forms of heart muscle disease. The collaboration builds upon MyoKardia`s pioneering science, which hopes to correct the disruptive effects that disease mutations have on heart muscle contraction. The collaboration, representing one of the research and development commitments to genetic forms of cardiomyopathy, encompasses three MyoKardia programs. Two of these programs are focused on hypertrophic cardiomyopathy (HCM) and the other is focused on dilated cardiomyopathy (DCM). The collaboration provides up to $200 million in equity investments, milestone payments and research and development services through 2018, of which $45 million has already been received in an upfront licensing fee and an initial equity investment. In addition, Sanofi and MyoKardia will equally share development costs on the HCM programs following initial demonstration of efficacy in patients, with Sanofi fully covering the development costs of the DCM program. The collaboration is an outgrowth of Sanofi`s Sunrise initiative, a strategic partnership model that seeks to invest in early stage opportunities that align with Sanofi`s expert development and commercialization abilities. The commitment of resources from Sanofi will accelerate and broaden MyoKardia`s basic disease research and will support the shared commitment of bringing desperately needed therapies to patients. Within the collaboration, MyoKardia will drive research and worldwide development activities through early human efficacy studies. Thereafter, MyoKardia will lead worldwide development and U.S. commercial activities for the two HCM programs, where it has retained product rights, and Sanofi will lead global development and commercial activities for DCM where it has obtained worldwide rights, and ex-U.S. regulatory and commercial activities to the two HCM programs where it has ex-U.S. commercialization rights. Sanofi also has the option to co-promote in the U.S. for potential expanded cardiovascular diseases outside of the genetically targeted indications for either of the HCM programs, with MyoKardia having the option to co-promote the DCM program in the U.S.
MyoKardia, Inc Appoints Mark L. Perry to Board of Directors
Nov 25 13
MyoKardia, Inc. announced the appointment of Mark L. Perry to its board of directors, joining Tassos Gianakakos, Charles Homcy, M.D., and Kevin Starr. Mr. Perry currently serves as chairman of the board of Pathway Therapeutics and director of Nvidia Corporation. Mr. Perry is also a member of the California State Bar Association and the Association of Bioscience Financial Officers, and serves on several nonprofit boards.
MyoKardia, Inc. Announces Management Changes
Oct 30 13
MyoKardia, Inc. announced the appointment of Tassos Gianakakos to chief executive officer. Mr. Gianakakos succeeds founding CEO Charles Homcy, M.D., who will remain on MyoKardia's board of directors. Mr. Gianakakos brings more than 17 years of broad-based biopharmaceutical expertise to MyoKardia. He joins the company from MAP Pharmaceuticals, where he was most recently senior vice president and chief business officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
August 1, 2014